Products Cited in Publications Worldwide Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma

Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma

Wang, Xuechun; Duong, Loan; Qin, Yujing; Parrotta, Rossella; Purohit, Paresh Kumar; Fang, Yihao; Liu, Guoqiang; He, Jianping; Wen, Jiling; Liu, Yan

DOI:

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of kidney cancer. Loss of von Hippel–Lindau (VHL) and the consequent activation of hypoxia-inducible factor-α (HIFα, especially HIF2α) plays an essential role in ccRCC initiation and progression. The approved HIF2α inhibitor belzutifan faces the challenge of resistance, presenting an opportunity of co-targeting HIF2α and another vulnerability. This study elucidates the synthetic essentiality of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) in VHL-deficient ccRCC, uncovering a novel reciprocal regulation between HIF2α and TRAIL. TRAIL was identified as a direct transcriptional target of HIF2α and paradoxically found to be crucial for cell proliferation, primarily by activating the p38 MAPK pathway and facilitating G1/S phase transition. Depletion of endogenous TRAIL or inhibition of HIF2α with belzutifan sensitizes ccRCC cells to recombinant TRAIL, presenting a promising avenue for combination therapy to overcome both TRAIL resistance and belzutifan resistance in treating ccRCC.

Keywords

TRAIL ; VHL ; HIF2α ; renal cell carcinoma ; belzutifan ; synthetic essentiality

Purchased from AmBeed

Belzutifan

A12167481672668-24-498%

Belzutifan

585.0/250mg

Detail